|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
Alexion Pharmaceuticals (2021)
|
|
gptkbp:businessModel
|
gptkb:public_company
|
|
gptkbp:CEO
|
gptkb:Pascal_Soriot
|
|
gptkbp:collaboratedWith
|
gptkb:University_of_Oxford
|
|
gptkbp:developedBy
|
gptkb:COVID-19_Vaccine_(Vaxzevria)
|
|
gptkbp:dividendPaying
|
yes
semi-annual
|
|
gptkbp:foundedBy
|
merger of Astra AB and Zeneca Group
|
|
gptkbp:foundedIn
|
1999
|
|
gptkbp:headquartersLocation
|
gptkb:Cambridge,_United_Kingdom
gptkb:London,_United_Kingdom
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AstraZeneca Group
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
GB0009895292
|
|
gptkbp:listedOn
|
gptkb:London_Stock_Exchange
gptkb:NASDAQ
|
|
gptkbp:logo
|
AstraZeneca logo.svg
|
|
gptkbp:marketCap
|
over $200 billion (2023)
|
|
gptkbp:memberOf
|
gptkb:S&P_500
gptkb:FTSE_100_Index
gptkb:S&P_100
|
|
gptkbp:memberState
|
over 100
|
|
gptkbp:netIncome
|
$5.97 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Crestor
gptkb:Farxiga
gptkb:Lynparza
gptkb:Symbicort
gptkb:Tagrisso
gptkb:COVID-19_Vaccine_(Vaxzevria)
|
|
gptkbp:numberOfEmployees
|
over 83,000 (2023)
|
|
gptkbp:officialWebsite
|
https://www.astrazeneca.com/
|
|
gptkbp:parentCompany
|
none
|
|
gptkbp:products
|
biopharmaceuticals
pharmaceutical drugs
|
|
gptkbp:regulates
|
gptkb:FDA
gptkb:EMA
gptkb:MHRA
|
|
gptkbp:researchInterest
|
immunology
oncology
rare diseases
cardiovascular
respiratory
|
|
gptkbp:revenue
|
$44.35 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:stockExchange
|
gptkb:London_Stock_Exchange
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
AZN
|
|
gptkbp:subsidiary
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:bfsParent
|
gptkb:AstraZeneca_AB
|
|
gptkbp:bfsLayer
|
6
|